Skip to main navigation Skip to search Skip to main content

An Open-Label, Multicenter, Non-Randomized, Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors

Press/Media

Period2026.06.12

Media coverage

1

Media coverage

  • TitleAn Open-Label, Multicenter, Non-Randomized, Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors
    Media name/outletVaccine Daily
    Country/TerritoryUnited States
    Date26.06.12
    PersonsGye-Mo Yang
View all 1
View less